JNJ•benzinga•
Johnson & Johnson Closes Intra-Cellular Therapies Acquisition; Expects Deal To Dilute Adj EPS By ~$0.25 in 2025
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 2, 2025 by benzinga